Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX

Tanios S. Bekaii-Saab

Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX

Interview with the Innovators

Pancreatic Cancer Patient Education

Videos

Featuring:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this ninth installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations for using NALIRIFOX or FOLFIRINOX when treating patients with pancreatic cancer.

Featuring:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX

Featuring:

Featuring:

Related Articles

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content